Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
TELA Bio, Inc. (TELA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Investor presentation, Quarterly results
Docs: "TELA Bio Reports Second Quarter 2023 Financial Results",
"Corporate Slide Deck"
05/11/2023 8-K Investor presentation, Quarterly results
Docs: "TELA Bio Reports First Quarter 2023 Financial Results",
"INVESTOR PRESENTATION May 2023"
03/21/2023 8-K Investor presentation, Quarterly results
Docs: "TELA Bio Reports Fourth Quarter and Full Year 2022 Financial Results",
"INVESTOR PRESENTATION March 2023"
01/10/2023 8-K Investor presentation
Docs: "INVESTOR PRESENTATION January 2023"
11/09/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
03/21/2022 8-K Investor presentation, Quarterly results
Docs: "TELA Bio, Inc. Consolidated Balance Sheets December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 43,931 $ 74,394 Accounts receivable, net 4,234 2,683 Inventory 7,658 3,907 Prepaid expenses and other assets 3,232 2,241 Total current assets 59,055 83,225 Property and equipment, net 1,186 626 Intangible assets, net 2,303 2,607 Total assets $ 62,544 $ 86,458 Liabilities and stockholders’ equity Current liabilities: Accounts payable $ 2,414 $ 652 Accrued expenses and other current liabilities 8,161 5,953 Total current liabilities 10,575 6,605 Long-term debt with related party 31,491 30,827 Other long-term liabilities 380 — Total liabilities 42,446 37,432 Stockholders’ equity: Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and outstanding —...",
"Advancing Soft Tissue Reconstruction Investor Presentation March 2022"
11/10/2021 8-K Investor presentation, Quarterly results
Docs: "TELA Bio, Inc. Consolidated Balance Sheets September 30, December 31, 2021 2020 Assets Current assets: Cash and cash equivalents $ 53,636 $ 74,394 Accounts receivable, net 3,573 2,683 Inventory 6,269 3,907 Prepaid expenses and other assets 2,061 2,241 Total current assets 65,539 83,225 Property and equipment, net 891 626 Intangible assets, net 2,379 2,607 Total assets $ 68,809 $ 86,458 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 2,334 $ 652 Accrued expenses and other current liabilities 7,043 5,953 Total current liabilities 9,377 6,605 Long-term debt with related party 31,315 30,827 Other long-term liabilities 388 — Total liabilities 41,080 37,432 Stockholders’ equity: Preferred stock; $0.001 par value: 10,000,000 shares authorized; no shares issued and ou...",
"Corporate Slide Deck"
03/29/2021 8-K Quarterly results
11/17/2020 8-K Investor presentation
Docs: "Corporate Slide Deck"
08/12/2020 8-K Quarterly results
05/22/2020 8-K Investor presentation
Docs: "Corporate Slide Deck"
04/01/2020 8-K Investor presentation
Docs: "Corporate Slide Deck"
01/10/2020 8-K Investor presentation
Docs: "TELA Bio Announces Preliminary Revenue for Fourth Quarter and Full Year 2019",
"Corporate slide deck, dated January 2020"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy